15-67187457-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_005902.4(SMAD3):c.1102C>T(p.Arg368*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_005902.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMAD3 | NM_005902.4 | c.1102C>T | p.Arg368* | stop_gained | Exon 8 of 9 | ENST00000327367.9 | NP_005893.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:2
The p.R368* pathogenic mutation (also known as c.1102C>T), located in coding exon 8 of the SMAD3 gene, results from a C to T substitution at nucleotide position 1102. This changes the amino acid from an arginine to a stop codon within coding exon 8. This alteration is located in the MH2 domain, which is involved in the oligomerization of the SMAD3/SMAD4 complex (Chacko BM et al Nat Struct Biol. 2001;8(3):248-53). This alteration has been described in a Loeys-Dietz syndrome type 3 cohort (Aubart M et al. PLoS ONE. 2014;9:e96387). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation. As such, this alteration is interpreted as a disease-causing mutation. -
This sequence change creates a premature translational stop signal (p.Arg368*) in the SMAD3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SMAD3 are known to be pathogenic (PMID: 21778426, 24804794). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with SMAD3-related conditions (PMID: 24804794). ClinVar contains an entry for this variant (Variation ID: 420088). For these reasons, this variant has been classified as Pathogenic. -
not provided Pathogenic:2
- -
Nonsense variant predicted to result in protein truncation, as the last 58 amino acids are lost, and other loss-of-function variants have been reported downstream in HGMD; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 28185953, 26221609, 30787465, 29392890, 31447099, 30118648, 34150014, 24804794, 30661052, 35031499, 35943490) -
Aneurysm-osteoarthritis syndrome Pathogenic:1
The c.1102C>T (p.Arg368*) variant in the SMAD3 gene is located in exon 8 (of 9) and is predicted to create a premature stop codon. This variant is predicted to result in an absent or aberrant protein product. This variant has been reported in individuals and families with familial thoracic aortic aneurysm and dissection (FTAAD), Loeys-Dietz syndrome type III or related disorders (PMID: 24804794, 29392890, 30661052, 34150014, 35031499). Truncating variants in SMAD3 are known to be pathogenic (PMID: 26333736, 32597575). ClinVar contains an entry for this variant (ID: 420088). Other stopgain or frameshifting variants downstream of this variant in the same exon have been reported to be pathogenic for FTAAD in ClinVar (IDs: 1730647, 582880, 1453411). This variant is absent in the general population database gnomAD (v2.1.1). Therefore, this variant is classified as pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at